Key result
Hepatic angiotensinogen siRNA emerges as a novel twice-yearly RAS blockade strategy to manage hypertension.
Why the study?
Antihypertensive RAS blockade can be inadequate due to poor adherence or the RAS escape phenomenon, prompting evaluation of hepatic AGT-targeting siRNA.
Does targeting angiotensinogen with N-acetylgalactosamine-conjugated small interfering RNA reduce blood pressure compared to classical RAS blockade?
Comparison
AGT small interfering RNA vs classical RAS blockade or AGT suppression with antisense oligonucleotides
Design
Review
Authors
Loading...
May offer long-acting hypertension option to improve adherence; leaves open superiority to classical RAS blockade pending RCTs.
Does targeting angiotensinogen with N-acetylgalactosamine-conjugated small interfering RNA reduce blood pressure compared to classical RAS blockade?
Targeting hepatic angiotensinogen with siRNA offers a novel, long-acting approach to hypertension management that may overcome poor adherence and the RAS escape phenomenon.
Ye et al. (2023) conducted a review in Hypertension. N-acetylgalactosamine-conjugated small interfering RNA targeting AGT vs. Classical RAS blockade or antisense oligonucleotides was evaluated. Targeting hepatic angiotensinogen with N-acetylgalactosamine-conjugated siRNA represents a novel approach to block the RAS pathway and manage hypertension with dosing 1 to 2 times per year.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: